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Ubiquilin (UBQL) is a member of type 2 ubiquitin-like (UBL) protein family. They 
structurally contain an N-terminal ubiquitin-like domain and a C-terminal ubiquitin-
associated (UBA) domain. Ubiquilin 2 (UBQL2) physically associates with poly 
ubiquitinated proteins and delivers them to the proteasome for degradation. This protein 
has been shown to play an important role in the regulation of aggregation and degradation 
of various neurodegenerative disease-associated proteins. In this study, we looked into 
the role of the ubiquilin-2 proteins in the AMPA receptor ubiquitination and proteasomal 
degradation pathway. Our results indicate that UBQL2 overexpression decreases AMPAR 
levels in neurons and also reduces GluA1 expression in HEK 293T cells. Moreover, by co-
immunoprecipitation we found that UBQL2 interacts with ubiquitinated AMPARs. We, 
therefore propose that UBQL2 brings AMPARs to the proteasome for degradation. 
Consistent with this notion, expression of UBQL2 P497H, a mutant form incapable of 
interaction with proteasome, causes accumulation of AMPA receptors. These results 
indicate a role for UBQL2 in associating with and directing ubiquitinated AMPA receptors 
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The mammalian nervous system is the most complex part of the body and its made 
up of billions of neurons all connected in a highly specialized manner to transmit 
cellular signals. These connections between neurons is what makes the brain 
function. These junctions between two nerve cells where the electrical signals are 
passed from one neuron to other are called as synapses. The neurons make up 
thousands of such synapses all relaying different information across the entire 
brain. This underlies the basic and higher order brain functions. The ability of the 
neurons to strengthen or weaken this connection forms the molecular and cellular 
basis of synaptic plasticity. Synaptic plasticity can be regulated at two levels. It can 
be either in the presynaptic neurons where it alters the efficacy of neurotransmitter 
released or in the post synaptic neurons that changes the number, types and 
properties of the neurotransmitter receptors. Thus the neurons drive all bodily 
functions by regulating these factors in the brain. 
  
1.1     AMPAR trafficking and turnover  
a-Amino-3-hydroxy-5-methyl-isoxazole-4-propionic acid receptors (AMPARs) are 
widely distributed post synaptic glutamate ion channels that mediate most of the 
synaptic transmission in the brain. The mammalian genome encodes for 4 subunits 
of AMPA receptors namely GluA1, GluA2, GluA3 and GluA4. They form dimers of 
dimers thus making up tetrameric structures. They are permeable to both Na+ and 
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K+ ions except the GluA2-lacking AMPARs which also conduct Ca2+ ions (Man 
2011, Widagdo et al. 2017). AMPARs are highly mobile structures. They are 
subjected to both constitutive (Man et al. 2000) and activity-dependent vertical 
trafficking (Borgdorff and Choquet 2002) between the plasma membrane 
and intracellular membrane compartments. The constitutive internalization 
between the plasma membrane and intracellular compartments was first studied 
using a hemagglutinin (HA)-tag to label surface and intracellular AMPARs in 
permeate and non-permeate conditions. It was found that homomeric HA-GluA1 
and HA-GluA2 subunits of AMPARs were expressed both on surface and in 
intracellular compartments. Further, this study also showed that the internalized 
GluA1 and GluA2 co-localized with eps15, which is an integral component of 
clathrin-coated vesicles.  Together these results provided evidence that AMPARs 
undergo clathrin mediated endocytosis from the plasma membrane (Man et al, 
2000).  
Other studies show lateral trafficking of AMPARs along the dendrites. The first 
study showing lateral movement used single particle tracking to look at surface 
AMPARs. They tracked the movement of a single beads of 0.5 μm, that were 
coated with antibodies against the extracellular domain of the AMPAR GluA2 
subunits and thus bound to surface AMPARs in the plasma membrane of cultured 
rat hippocampal neurons. They showed that surface AMPARs alternated between 
the states of lateral diffusion and stable structure. These stable structures were 
present near synapses and thus this defined the understanding of surface 
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dynamics of AMPARs (Borgdorff and Choquet 2002). Subsequently there were 
several others who used unique techniques to visualize the AMPARs dynamics. 
One group made use of an irreversible antagonist of AMPA receptors, ANQX to 
silence the surface AMPAR and look at native AMPAR trafficking along the 
dendrite. They reported the movement of AMPAR occurring laterally across the 
surface of the neurons (Adesnik Hillel et al. 2005). Most other studies show that 
AMPARs use kinesis and dynein vesicles for trafficking along the dendrites to 
reach the synapse (Ko Jaewon et al. 2003). Recently it has been shown that there 
is the involvement of Ca2+ motor protein- myosin in the trafficking of GluA1 
containing AMPARs (France-Lise Marie et al. 2005).  
Of particular interest is the trafficking of AMPAR during synaptic plasticity where 
they undergo insertion and removal from the membrane in an activity dependent 
manner. Synaptic plasticity requires the neuron to adapt to the changes in the 
synaptic strength and neuronal activity. One of the best known model of synaptic 
plasticity is the Hebbian-type plasticity. Examples of Hebbian style plasticity is long 
term potentiation (LTP) and long-term depression (LTD). During an LTP condition, 
high frequency stimulation causes the insertion of AMPAR to the membrane 
thereby causing increased synaptic activity (Hughes John 1958). This can last from 
minutes to hours (Henley Jeremy and Wilkinson Kevin 2013). On the other hand, 
low frequency stimulation causes decrease in synaptic activity and removal of 




The number of AMPARs on the membrane therefore depends on the relative rates 
of endocytosis and exocytosis at the post synaptic membrane. At the molecular 
levels it has been reported that PI3 kinase plays an important role in insertion of 
AMPARs during glycine-induced LTP conditions through receptor phosphorylation 
and activation (Man et al. 2003). The regulation of AMPARs takes place in the 
intracellular domain of AMPARs where they contain long and short tails. This 
determines their trafficking. GluA1 and GluA4 have long-tails while GluA1 and 
GluA3 contain short tails.  GluA4 is expressed mainly during early development 
and is present only at low levels in adult brain. The trafficking properties of long-
tailed AMPAR subunits predominate over those of short tailed subunits, so 
receptors containing the GluA1/2 subunit combination exhibit the surface 
trafficking properties of GluA1. However, GluA1/A3 AMPARs are also recycled to 
and from the membrane but relatively slowly. Hence during LTP conditions GluA1 
is replaced in synapse in an activity dependent manner and slowly replaced by 
GluA2/GluA3 (Henley Jeremy and Wilkinson Kevin 2013). This regulation of 
AMPAR trafficking involving the insertion and removal of AMPARs occurs through 
an orchestrated number of AMPAR binding proteins and as well as post 
translational mechanism such as phosphorylation (Man et al. 2007, Diering et al. 
2016), acetylation (Wang et al. 2017) and ubiquitination (Lin et al. 2011, Lin et al. 
2014, Huo et al. 2015, Zhang et al. 2018). The carboxyl termini of AMPAR subunits 
contains multiple regulatory elements that are subjected to these various post-
translational modifications (Lu et al. 2011).  
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1.2 Ubiquitination mechanism and AMPAR regulation 
One such unique post translational modification is the ubiquitination mechanism. 
This is a reversible modification and has emerged as an important regulator of 
AMPAR trafficking, endocytosis and protein degradation function (Lin et al. 2011, 
Goo et al. 2015). Ubiquitin is a small 76 amino acid protein ubiquitously expressed 
in all eukaryotes. Ubiquitin can be covalently conjugated to lysine residues on other 
proteins substrate through a series of reactions catalyzed by three enzymes: E1–
E3. The attachment process is initiated by an ubiquitin activating enzyme, E1, 
which activates ubiquitin by forming a thioester bond between the carboxyl 
terminus of lysine residue of the ubiquitin and the thiol group of a specific cysteine 
residue of E1. The ubiquitin moiety is transferred to an ubiquitin conjugating 
enzyme, E2, which functions with an ubiquitin protein ligase E3 enzyme to transfer 
ubiquitin onto a protein substrate. The E3 enzymes catalyze the formation of an 
isopeptide bond between the carboxyl terminus of ubiquitin and the Ɛ amino group 
of a lysine residue on the target protein (Lin et al. 2013, Cecile et al. 2001). 
Polyubiquitin chains result from attaching additional ubiquitin moieties to internal 
lysines of the previously attached ubiquitin polypeptide. If the polyubiquitin tail 
contains three or more ubiquitin molecules, the protein is sent to the proteasome 
for degradation (Fig. 1). Importantly, the ubiquitin-proteasome system is crucial in 
regulating AMPAR trafficking and turnover (Lin et al. 2013, Kleijnen et al. 2003). 
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There are only 2 E1 and 30-50 E2 genes, while there are over 600 human E3 
ligase genes. Activation of AMPARs by AMPA or Glutamate can recruit various E3 
ligases that dictate the ubiquitination process (Hershko et al. 1998, Grzegorz et al. 
2006, Lin et al. 2011). 
The E3 ligases can be classified into three families based on their functionality. 
One of them is RING type E3 ligases i.e. the Really Interesting New Gene (RING), 
second one is the homologous to E6-AP C-terminus (HECT) type E3 ligases and 
third type is the RING-between-RINGs (RBRs). The RING type enzymes ensures 
close proximity between the ubiquitin-E2 complex and the protein substrate such 
that the ubiquitin is directly transferred from the E2 enzyme to the protein 
substrate. The HECT type ligases ensures that the ubiquitin molecule binds 
covalently to their catalytic HECT domain via a cysteine residue and then shuttle 
it onto the target molecule (Mateusz et al. 2015). The RBRs are a hybrid of RING-
HECT mechanism that contains an E2-binding RING domain and a second RING 
domain with active cysteine to form the E-Ub intermediate (Dove Katja K and Klevit 
Rachel 2017). The vast majority of human E3 enzymes belong to the RING family 
while only 28 are of the HECT type (Mateusz et al. 2015). The consequences for 
the modified target protein are determined by the type of polyubiquitin modification. 
Ubiquitination can result in the change of function, localization or activity of the 
modified protein, or control its degradation via the 26S proteasome. 
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The Nedd4 subfamily is the largest and best characterized family of the HECT E3s. 
The N-terminal C2 domain is defined as a Ca2+ and phospholipid binder (Sluimer 
et al. 2018). Nedd4 is a highly expressed HECT type E3 ligases in neurons. The 
C2 domain can also bind to substrate proteins to target them for ubiquitination. It 
was shown to induce ubiquitination of AMPARs in neurons. Further results 
indicated that nedd4 induces the surface stability of AMPARs (Lin et al. 2011). 
The first evidence demonstrating ubiquitination of GluA1 subunit of AMPARs was 
revealed in C. elegans. This study showed that the ubiquitination of AMPARs 
decreased the glutamate receptor synaptic accumulation suggesting the role of 
ubiquitination in regulation of glutamate receptors 
(Burbea et al. 2002).  Subsequently, there have been several studies reporting the 
ubiquitination process of AMPAR subunits and how it serves as a signal to trigger 
endocytosis and direct the protein to the proteasome/lysosome for degradation 
(Patrick et al. 2003, Lin and Man 2013, Lin et al. 2011).  
Previously our study has shown that AMPARs are subject to Nedd4-mediated 
ubiquitination, leading to a reduction in cell-surface receptor expression and 
suppressed synaptic transmission (Lin et al. 2011 and Lin and Man 2014). There 
have been several others indicating that ubiquitination of all four subunits of 
AMPARs (Widagdo et al. 2017). Further regulation also occurs by removal of the 
ubiquitin from AMPARs by deubiquitinases. One such deubiquitinases is the 
USP46 that is specific for regulating AMPARs and causes increase in levels of 
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surface AMPARs and decrease ubiquitination when overexpressed (Huo et al. 
2015).  
Other mechanism of AMPARs regulation begins by binding of a ligand to the GluA1 
surface receptors (Widagdo et al. 2017).  The GluA1 can also be stimulated using 
bicuculline which releases glutamate from the presynaptic terminal leading to 
activation of AMPARs in the post synaptic end. Apart from ligand binding there is 
also the depolarization of membrane due to inflow of sodium into the cell. Sodium 
inflow opens the AMPARs and also causes the calcium inflow through the N-
Methyl-D-aspartate receptor (NMDAR) or voltage gated calcium channel (VGCC), 
which is also required for AMPARs ubiquitination (Widagdo et al. 2017, Zhang et 
al 2018). GluA1 levels have also been found to be decreased by ubiquitination in 
presence of amyloid-beta (Aβ) in Alzheimer’s disease (AD) condition and autistic 
conditions (Purcell et al. 2001, Guntupalli et al. 2017, Zhang et al. 2018). In 
neurons, GluA1 ubiquitination occurs on residue lysine868 in the carboxyl terminal 
tail (Lin et al. 2011). Upon ubiquitination, a portion of internalized GluA1 is 
degraded either by the lysosome or proteasome and the rest recycled by 
endosomes back to the membrane. This controls the total level of GluA1 in 
neurons (Lu et al. 2011). This process mediated by the ubiquitin-proteasome 
system (UPS) is a highly regulated proteolytic pathway and it’s the most important 




Fig. 1.  
Ubiquitin-proteasome system in mammals. The schematic shows the main steps 
of the ubiquitin-proteasome pathway. 1) E1 binds to ubiquitin by consumption of 
one ATP to AMP in order to activate it. 2) The ubiquitin-carrier enzyme E2 takes 
over the ubiquitin from E1. 3) E2 transfers the ubiquitin to a protein substrate bound 
to the ubiquitin ligase, E3. 4) The ubiquitin chain is extended. Each step of the 
extension can be reversed by a deubiquitinating enzyme. 5) A ubiquitinated protein 
bound with either 1, 2, 3 or 4 ubiquitin molecules binds to the 26 S proteasome in 




1.3 Fate of ubiquitin tagged protein  
The ubiquitin chain acts as a tag for the determining the fate of the protein. Tagging 
of ubiquitin by a K48 linkage on an ubiquitin molecule leads to the protein 
degradation by proteasome. Whereas tagging on a K63 is for protein signaling, 
enzyme activity in proteasome independent manner (Yasushu et al. 2017). On the 
other hand, deubiquitinases (DUBs) can act on the protein to remove the ubiquitin 
chains on the protein (Lin et al. 2011, Huo et al. 2015).  
Degradation at the proteasome is the final step in the UPS system. The 
proteasome is a 2.5MDa complex protein made up of 33 smaller subunits, 
arranged into an elongated tube called 20S central core particle(CP) and one or 
more 19S regulatory particles(RP) consisting of a base and a lid subunit. The CP 
consists of two outer α rings and two inner β rings, which are composed of seven 
structurally similar α and β subunits, respectively. Three of the seven β subunits 
have proteolytic sites (β1, β2, and β5; caspase-like, trypsin-like, and chymotrypsin-
like activities, respectively) on the inner surface of the chamber formed by two 
abutting β rings. The combination of multiple active sites with different selectivity  
contributes to rapid and progressive degradation of substrates that have entered 
the catalytic chamber (Keiji et al. 2012).  The RP consists of six ATPase subunits 
(Rpt1–6) and 13 non-ATPase subunits (Rpn1–3, 5–13 and 15), which play roles in 
processing ubiquitinated proteins.  
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The ubiquitin receptor subunits (such as rpn10, rpn 3) capture the ubiquitinated 
substrates and the ATPase subunits helps in substrate unfolding and translocation 
into the CP (Budenholzer et al. 2017, Yasushi et al. 2017). This process requires 
the ATP hydrolysis.  In the 26S proteasome, the deubiquitinase activity of the lid 
Rpn11 subunit cleaves ubiquitin chains from proteasomal substrates. The protein 
is passed to the 20S proteasomal core containing protease that breaks down the 
proteins into their degradation products (Hongmin et al. 2018, Walters et al. 2002). 
 
1.4  Ubiquilins as shuttling proteins in proteasomal degradation pathway 
Protein Linking IAP and  Cytoskeleton(hPLIC) proteins, also referred to as 
Ubiquilins(UBQLs), are human orthologs of the yeast Dsk2 family of proteins. 
Ubiquilins have been known to act as shuttling proteins in bringing other ubi tagged 
substrates to the proteasome (Ipsita Subudhi and James Shorter et al. 2018). 
UBQLs consists of a family of four homologous proteins- UBQL1, UBQL2, UBQL3 
and UBQL4. All contain a ubiquitin-like (UBL) amino-terminal domain; a body 
region containing stress inducible (STI) heat-shock protein binding motifs and a 
carboxyl terminal ubiquitin associated domain (UBA). UBQL1 and UBQL2 are 
localized in cytoplasm of the cells. UBQL1 is present in all cells of the body tissues. 
This protein acts as a molecular chaperone for the amyloid precursor protein (APP) 
and it is reported in Alzheimer’s disease (AD) condition (Liang et al. 2014, 
Kurlawala et al.2017). Also, a particular polymorphism of UBQL1 can lead to a 




UBQL2 is specifically and highly expressed in brain and muscle region. Several 
studies outline the role of UBQL2 in degradation pathway and its association in 
several neurological disorders (Liang et al. 2014). 
 
Fig. 2. 
Structural domains of ubiquilin family of proteins (A)Schematic showing the 
different domains and motifs of Ubiquilin-2. It contains a well characterized N-
terminal UBL (ubiquitin like) domain and a C-terminal UBA (ubiquitin associated) 
domain. Interspersed between the two is the Body region which contains four Sti1 
like domains and a repeat of twelve PXX motifs also called collagen-like domain 
(Pro-X-X; where X can be any amino acid residue). (B) Below is the schematic 
diagram showing the different domains and motifs of other ubiquilin family of 
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proteins. They are all similar to UBQL2 and contain UBA and UBL domain but do 
not contain the twelve repeat PXX domain.  
 
UBQL2 is also reported to be involved in distinct cellular process like endoplasmic 
reticulum associated degradation (ERAD) pathways and autophagy pathways 
(Zhang et al. 2014, Brown et al. 2016).  
 
The UBQL2 is encoded by a gene containing a single 1.875kb coding exon. This 
is an intron-less gene that maps to the X chromosome in vertebrates. It is similar 
to other UBQLs family of proteins that contain a UBL, UBA and the STI domains, 
but it is distinct from UBQLs in that UBQL2 contains a unique collagen rich domain 
containing 12 PXX tandem repeats (Fig. 2). This domain may be important for 
UBQL2 protein-protein interaction, and also some of the differences in binding 
partners between UBQL2 and other UBQLs. Ubiquitin ligases such as E6AP, add 
polyubiquitin chains on to the protein substrate. UBQL2 physically associates with 
ubiquitin tagged protein substrate through the UBA domain and the proteasome 
through the UBL domain and bring the ubi tagged protein to the proteasome for 
protein degradation (Zhang et al. 2014). Several mutations in UBQL2 impair the 
function of proteasome binding causing accumulation of the proteins. Such 
mutations are seen in amyotrophic lateral Sclerosis-fronto-temporal dementia 
(ALS-FTD) conditions (Zhang et al. 2014). 
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The UBA domain binds to the poly ubiquitin tail on the protein substrate. The 
UBQL2 mutants having the UBA deletion failed to bind to the poly ubiquitin tails. 
Also, the mutant containing only the UBA domain can still bind to the poly ubiquitin 
tails. Thus, UBA domain is sufficient for the binding of UBQL2 to polyubiquitin tail 
(Han et al. 2004). On the other side of UBQL2, the UBL domain is able to bind to 
the 19S cap subunits of the proteasome. The ability of UBL domain to bind to the 
proteasome was assessed through pull down experiments. UBL domain was 
shown to bind to the rpn lid subunits such as rpn3, 10, 13 of the proteasome.  In 
this way, UBQL2 is successful in bringing the ubi tagged protein closer to the 
proteasome for degradation (Rothenberg et al. 2010). 
 
Several studies on UBQL2 have shown that there are the most common proteins 
to be mutated in the ALS condition (Caballero-Harnandez et al.2016, Sang et al. 
2018, Han-Xiang et al. 2011, Alexander et al. 2018). They exhibit defective 
proteasome binding leading to protein accumulations in the neurons (Eykens et al. 
2015, Stegmuller et al. 2016). One such mutation discussed here is the single 
amino acid mutation (P497H) in the PXX domain of UBQL2 (Talbot et al.2018). 
This has been shown to cause insoluble aggregates in cells. These aggregates 
co-localize with ubiquitin, fused in sarcoma protein (FUS), p62, optineurin, and 
occasionally to Trans active response DNA binding protein (TDP-43), therefore 
leading to neurodegenerative disorders (Ceballos et al. 2015, Jantrapirom et 
al.2018) (Fig. 3).  
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Not a lot of study has been done on UBQL3 and UBQL4 mostly because of their 
scarce nature. But it has been found that UBQL3 is predominant in testis and 
UBQL4 is localized in cell nucleus (Kleijnen et al. 2003, Khiem et al. 2017). 
 
1.5 Rationale and hypothesis of the study  
Previous studies of our lab provide evidence that AMPARs are subjected to 
ubiquitination in the brain and establish important roles for ubiquitination 
mechanism in AMPARs trafficking and degradation (Lin et al. 2011). They show 
that ubiquitinated AMPARs are internalized via the Eps15 adaptor protein 
mediated endocytic pathway (Lin et al. 2014). The ubi-tagged AMPARs are 
subjected to proteasomal degradation (Lin and Man 2013). However, the 
mechanism by which these ubiquitinated AMPARs are coupled to the proteasome 
remains unknown. UBQL2 is capable of binding to both the polyubiquitin chain on 
a target protein and to the proteasome subunits. Therefore, we hypothesize that 
once the AMPARs are internalized upon ubiquitination, UBQL2 binds to the 
ubiquitinated AMPARs and brings the receptor to the proteasome for degradation. 
Here, we study the interaction between UBQL2 and GluA1 subunit of AMPARs in 







Difference in binding between WT-UBQL2 and mutant UBQL2. The above 
schematic shows that WT-UBQL2 can bind to polyubiquitinated proteins and 
deliver them to the proteasome for degradation. On the other hand, the mutant 
UBQL2 can bind the polyubiquitinated proteins but blocks proteasomal 













2.1 Neuronal cell culture preparation and HEK cell culture  
Primary cultured cortical and hippocampal neurons were prepared from embryonic 
day 18 rat embryos. Briefly, embryonic brain regions were dissected and digested 
with papain at 37°C. Dissociated neurons were seeded onto Poly-L-lysine-coated 
coverslips at approximately 3 × 106 cells per 60 mm dish, each containing five 
coverslips. Neurons were maintained in Neurobasal medium (Gibco, Rockville, 
MD, USA) supplemented with 2% B27, 1% horse serum, 1% 
penicillin/streptomycin, and 0.4% L-glutamine for 2–3 weeks until use. One week 
after plating, 5-fluorodeoxyuridine (5 μM) was added to the media to inhibit glial 
growth. All cells were maintained in a humidified incubator containing 5% CO2.  
Human embryonic kidney (HEK) 293T cells were cultured in 60mm dish in 
Dulbecco’s Modified Eagle Medium (Gibco) supplemented with 10% heat-
inactivated fetal bovine serum and 1% penicillin/streptomycin and passaged at 
100% confluence twice a week.  
2.2 Rat brain dissection 
The adult rat brain was dissected immediately after euthanizing it in CO2 chamber. 
The dissecting instruments such as razor, forceps, scissors were sterilized by 
dipping in 70% ethanol and kept on ice. The petri dish containing ice cold 1X 
phosphate buffer saline (PBS) was placed on an ice bucket. The animal was first 
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cut from the neck region and the skull torn apart using a sharp scissor. The brain 
was taken out using forceps and placed on the ice cold petri dish. The brain was 
then cut in half through the hemispheres using the razor. The olfactory bulb was 
removed first. The prefrontal cortex was then cut and the tissue was put into a 
chilled Eppendorf tube containing cold Radioimmunoprecipitation assay buffer 
(RIPA) (0.1% sodium dodecyl sulphate (SDS)). The tissue was gently grinded 
using a pestle and was sonicated at setting 4 for approximately 5 seconds, five 
times. This was done in the 4ºC room. The samples were then placed on the 
rotating arm at 4ºC and allowed to rotate for 30 minutes – 1 hour. The samples 
were centrifuged at max speed (13,000 RPM) using at 4°C in a micro-centrifuge 
for 10 min. The supernatant was removed and placed into a new 1.5 mL micro-
centrifuge tube on ice and the pellet was discarded. The bicinchoninic acid (BCA) 
assay was done on the lysate by diluting it 100 times in 0.1% SDS RIPA buffer. 
The total amount of protein present was noted and approximate amount of 500µg 
was used for co-immunoprecipitation experiments.  
2.3 Transfection in neuronal cell culture and HEK cells 
2.3.1 Neuronal transfection 
Coverslips at about 14-days in vitro of the hippocampal neurons were first 
transferred to a 12-well plate and were transfected with Lipofectamine 2000 
(Invitrogen) according to the manufacturer's protocol. For one coverslip, DNA was 
added (1 μg of each) and Lipofectamine 2000 (2 μl) was added, and incubated at 
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room temperature for 20 min. The DNA complex was then added to a well 
containing one coverslip with 0.5 ml of culture medium and kept in the incubator. 
After 3-h incubation, the transfection medium was removed and replaced with fresh 
1ml culture medium until the further use.  
2.3.2 HEK cells transfection 
Transfections were performed in 60mm dish at approximately 50–70% confluency 
using Calcium phosphate method. For each dish, 2µg of DNA with 10 μl of CaCl2 
were mixed with 100 μl of the HEPES transfection reagent. The mixture was 
pipetted vigorously to form DNA-calcium phosphate co-precipitate and this was 
added to the culture dish. They were incubated for 1.5 – 2 days in the humidified 
incubator containing 5% CO2 after which the cells were lysed for biochemical 
analysis. 
2.4 Immunostaining of neuronal cells 
Three days following the transfection of neuronal cells, they were fixed and 
immunostained. The immunostaining was performed in 12 well plate. The culture 
media was first aspirated and the cells were washed in 1X PBS. They were then 
fixed using 500 μl of fixation solution (4% paraformaldehyde, 4% sucrose in 1X 
PBS, pH 7.4). The cells were covered with aluminum foil and incubated for 10 min 
in room temperature. The fixation solution was then removed and cells washed 
twice in 1X PBS. The cells were permeabilized with 0.3% triton- X for 10min in 
room temperature. The cells were washed and then blocked with 10% Goat serum. 
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The plate was incubated for 30min at room temperature. The primary antibody 
solution was prepared in 2.5% Goat serum solution diluted in 1X PBS. The rabbit 
GluA1-C terminal antibody was used in the ratio of 1:250 and mouse GluA1 was 
used at 1:500 dilutions. The rabbit UBQL2 antibody was used at 1:500 dilutions. 
The mouse rpn 3 antibody was also used at 1:500 dilutions. 125 μl of the primary 
antibody solution was put into a Para film surface. The coverslips were then 
transferred onto a para film surface such that they were completely submerged 
into the primary antibody. The cells were covered and placed in cold room at 4ºC 
overnight. The cells were taken out of the cold room the next day and put into the 
wells containing 1X PBS solution. They were washed twice in PBS solution. The 
secondary antibody was diluted to 1:500 and added to each well. They were 
incubated for 1 hr. The coverslips were washed in 1X PBS thrice and then mounted 
using the prolong gold antifade solution(Invitrogen) and kept in the dark for 4 h 
before imaging.  
2.5 Biochemical analysis of protein 
2 days after transfection, HEK293T cells were lysed. HEK cells were first rinsed 
with cold PBS buffer and cells collected in 200 μL modified RIPA lysis buffer [10 
mM Tris-HCl pH 7.4, 150 mM NaCl, 0.1% Triton X-100, 1% Sodium deoxycholate 
(SDOC) and 0.1% SDS, 5mM Ethylenediaminetetraacetic acid(EDTA)] containing 
mini cOmplete protease and phosphatase inhibitors (Hoffmann-La Roche 
Grenzacherstrasse, Basel, Switzerland). Lysates were further solubilized by 
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sonication and 10 min incubation on ice followed by centrifugation for 10 min at 13 
000 g. The pellet was discarded and supernatant used for further processing. Cell 
lysates were resuspended in 2X laemmli buffer and denatured at 95°C for 10 min. 
Immunoprecipitates and the lysates were analyzed by western blotting. The gels 
containing 6% separating and 5% stacking were prepared according to Harlow 
et.al.  The samples were loaded and run at 90V for 15min and 100V for 45min. 
The protein was then transferred to polyvinylidene difluoride membranes. The 
transferring was done at 400mA for 90 mins. The membrane was then probed with 
the appropriate antibodies.  The antibodies used were GluA1 C terminal (1:2000), 
UBQL2(1:1000), e6AP (1:1000), rpn3(1:2000). Immunointensity of western blots 
was measured using ImageJ.  (Wayne Rasband National Institute of Mental 
Health, MD, USA). 
2.6 Co-immunoprecipitation assay 
First the concentration of total protein in the lysate were determined using a BCA 
assay. For co-immunoprecipitation assay, 500µg of the protein was used. 
Appropriate amount of lysate was taken and adjusted to 500 μL with RIPA lysis 
buffer and incubated overnight on rotation at 4°C with antibodies against glutamate 
receptor subunit 1 (GluA1) or UBQL2 and protein A-Sepharose beads (Santa Cruz 
Biotechnology, Santa Cruz, CA, USA). Immunocomplexes were washed three 
times with ice-cold RIPA buffer without SDS (50 mM Tris-HCl pH 7.4, 150 mM 
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NaCl, 1% NP40, 1% SDOC), resuspended in 2X Laemmli buffer and denatured at 
95°C for 10 min.  
2.7 Image collection and analysis 
Mounted slides were imaged using an inverted fluorescence microscope at a 63× 
with an oil immersion objective (Zeiss Axiovert 200M, Carl Zeiss, Carl-Zeiss-
Straϐe, Oberkochen, Germany). The exposure time for fluorescence signal was 
first set automatically by the software then adjusted manually so that the signals 
were within the full dynamic range. The glow scale look-up table was used to 
monitor the saturation level. When analyzed using ImageJ software, images were 
manually thresholded to select GluA1 puncta for quantitative measurements. For 
immunostaining image analysis, 60–100 μm of at least three segments of 
secondary dendrites from different neurites were analyzed to represent one 
neuron. The intensity was measured by puncta size multiplied by fluorescence 
which would give the protein level. The same threshold was used when measuring 
the same batch of images. For co-localization analysis, the ImageJ plugin 
colocalization was used. The two channels were merged and the threshold for 
each channel was set and used across all conditions uniformly. The merged image 
was analyzed for the percent area that was colocalized and the value was plotted 
for each condition. The spine density was measured by counting the number of 
spines on a 60-100µm piece of secondary dendrite. The values were averaged for 
three different regions for a single neuron.  
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2.8 Western quantification 
The western bands were analyzed and quantified using ImageJ. The same area 
within each lane was selected and measured for intensity. Any background was 
subtracted across lanes. The peak area value was noted and graph plotted using 

















3.1 UBQL2 interacts with GluA1 subunit of AMPA receptors 
UBQL2 is abundantly found in cytosol of the cell where it is showed to have several 
protein binding function (Han Seok Ko et al, 2004). To study the interaction 
between UBQL2 and GluA1, previous student in our lab used rat hippocampal 
neurons and double stained UBQL2 and GluA1 using anti-UBQL2 antibody and 
anti-GluA1 antibody respectively. The results show that UBQL2 and GluA1 co-
localize in the same region (Fig. 4A). To study the interaction in vivo, adult rat brain 
was dissected and the pre frontal cortical region was carefully taken out. The lysate 
was made using the above mentioned steps. GluA1 was immunoprecipitated (IP) 
with anti-GluA1 antibodies. As a control, IgG was added to the same volume of 
lysate that was used for GluA1 IP. They were detected by western blotting using 
anti-UBQL2 which showed interaction with GluA1. Further to confirm the pull down, 
anti-GluA1 antibodies were used. The results indicate there is an interaction 
between UBQL2 and GluA1 (Fig. 4B). To test if the interaction occurs when anti-
UBQL2 antibodies were immunoprecipitated, UBQL2 was immunoprecipitated 
using anti-UBQL2 antibodies along with an IgG control. There was a clear band 
when probed for GluA1 indicating that GluA1 and UBQL2 interact with each other 
(Fig. 4C). The membrane was re-probed with anti-UBQL2 antibodies to confirm 





UBQL2 and GluA1 can interact with each other in rat brain (A) Cultured DIV 11 rat 
hippocampal neurons were immunostained with anti-UBQL2 and anti-GluA1 
antibodies. The merge of channels shows the co-localization of UBQL2 and GluA1. 
The boxed area is enlarged and the arrows depict the co-localized puncta 
(Courtesy to Ouyang Guo) (B) The lysate from rat brain were immunoprecipitated 
with anti-GluA1 antibody and probed with anti-UBQL2 antibodies. The pull down 
was confirmed using anti-GluA1 antibody.  The top band in input for UBQL2 is a 
nonspecific band. The darker band shows the level of input. (C) Rat brain was 
dissected and lysates were prepared using the RIPA lysis buffer and UBQL2 was 
immunoprecipitated using the anti-UBQL2 antibody and probed with anti-GluA1. 






3.2 C terminal domain of GluA1 is required for UBQL2 interaction  
Since ubiquitination is post translational mechanism that occurs in the intracellular 
C terminal domain of GluA1 (Lu et al. 2011), we looked at how C terminal deletion 
domain of GluA1 effect the interaction with UBQL2. HEK293T cells were co-
transfected with GFP tagged full length GluA1 (GFP-FL GluA1) or the GluA1 C 
terminal deletion (GFP-GluA1∆C) along with UBQL2. GFP transfected with UBQL2 
was used as a control. The cells were lysed after 2 days of transfection and 
immunoprecipitated with anti-GFP antibodies. The interaction with UBQL2 was 
tested using the anti-UBQL2 antibody. The GluA1∆C group showed reduced 
interaction with UBQL2 compared to the FL- GluA1 group. However, the lysates 
showed clear bands for both UBQL2 and GluA1 (GFP) suggesting that there was 
UBQL2 present in the cytoplasm but was incapable of interacting with GluA1 when 
the C terminal was deleted (Fig. 5A).  
A student T-tests were performed based on two different trials with a confidence 
limit of 0.05. The intensity of the bands was calculated using ImageJ software and 
the graphs plotted shows significant difference in binding of UBQL2 with FL GluA1 





C terminal domain of GluA1 is necessary for UBQL2 binding. (A) HEK293T were 
transfected with Full length GFP- GluA1 or GFP- GluA1 C terminal deletion mutant 
along with UBQL2. The GluA1 was immunoprecipitated with anti-GFP antibodies 
and probed with anti-UBQL2 antibodies. The membrane was probed with anti-GFP 
for confirmation of the pull down. The lysate levels were probed with anti-GFP and 
anti-UBQL2 antibodies showing there is UBQL2 present in control and transfected 
cells. (B) The quantification of intensity of binding of GluA1 with UBQL2. All 
intensity was standardized with GluA1 pull down levels. The ratio of UBQL2 
binding to A1 was calculated and the graph plotted for the intensity of UBQL2. 






3.3 Lysine residues in GluA1 C-terminal domain is necessary for UBQL2 
interaction 
 From previous result it was shown that UBQL2 binding takes place through the C 
terminal domain of GluA1 where ubiquitination occurs. To further evaluate the ubi-
dependency in the C terminal domain of GluA1, we used a GluA1 construct that 
has all the 4 lysines in the C terminal domain mutated to arginine-GluA14KR. Since 
ubiquitins bind to lysine residue of a protein to form a polyubiquitin chain, this 
mutation would prevent any ubiquitin to bind to GluA1. 
To determine the effect of this mutation on interaction with UBQL2, HEK293T cells 
were transfected with either WT GFP-GluA1 or GFP-GluA14KR along with UBQL2.  
The GFP transfected with UBQL2 was used as a control. The cells were lysed and 
immunoprecipitated with anti-GFP antibodies to capture the GluA1. The binding of 
UBQL2 to the immunoprecipitated GluA1 was accessed using anti-UBQL2 
antibodies. 
As shown in Fig 6A, the GluA14KR showed lesser interaction with UBQL2 
compared to the WT GluA1. The lysates however showed bands for UBQL2 and 
GluA1 indicating the presence of protein in the cell. This suggested that UBQL2 
was unable to bind to GluA1 as when it had the K to R mutation in its C terminal 
domain. Thus, GluA1 requires the formation of a polyubiquitin tail through its lysine 
residues for effective binding with UBQL2 (Fig. 6A). Since polyubiquitin tail in 
GluA1 is formed at the lysine 868 site, we used a construct that has a point 
mutation at K868 mutated to arginine (R). Results shows that when GluA1 is 
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immunoprecipitated, the levels of UBQL2 interaction decreases with GluA1K868R 
(data not shown). Thus GluA1 binding to UBQL2 is through ubiquitin dependent 
pathway. 
A student T tests was performed for two trials and the confidence limit set to 0.05. 
The graphs plotted shows significant reduction of binding to UBQL2 in GluA14KR 





 Lysine residues on GluA1 C terminal are required for UBQL2 binding. (A) 
HEK293T were transfected with Full length GFP- GluA1 or GFP- GluA1 4KR 
mutant along with UBQL2. The GluA1 was immunoprecipitated with anti-GFP 
antibodies and probed with anti-UBQL2 antibodies. The membrane was probed 
with anti-GFP for confirmation of the pull down. The lysate levels were probed with 
anti-GFP and anti-UBQL2 antibodies showing there is UBQL2 present in control 
 
30 
and transfected cells. (B) The quantification of intensity of binding of GluA1 with 
UBQL2. All intensity was standardized with GluA1 pull down levels. The ratio of 
UBQL2 binding to A1 was calculated and the graph plotted for the intensity of 
UBQL2. (UBQL2/A1 = 0.74 ± 0.03; UBQL2/A14KR = 0.05 ± 0.01; n = 2; p < 0.05). 
UBQL2 interacts with GluA1 through the lysine868 on the C terminal domain. 
 
3.4 Overexpression of UBQL2 causes GluA1 reduction 
Further, to investigate if UBQL2 overexpression has any effect on total GluA1 
levels, the cultured hippocampal neurons were transfected at DIV 11 with GFP and 
together with and without UBQL2. The transfected dishes were left for 3 hours after 
which the media was changed. Three days after transfection, the GluA1 puncta 
density and intensity were analyzed. There was a decrease in the GluA1 puncta 
density and intensity with the overexpression of UBQL2 (Fig. 7A). The 
quantification of intensity and density were done by the above mentioned steps 
(Fig. 7B). This result indicates that UBQL2 might be possibly playing a role in 
GluA1 degradation pathway. 
To confirm the above observations, the HEK293T cells were transfected with 
GluA1 along with and without UBQL2. The cells were lysed using RIPA buffer after 
2 days. The total GluA1 levels were quantified using western blotting. The levels 
of GluA1 decreased when UQBL2 was over expressed in HEK293T cell (Fig. 7C).  
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The intensity of each band was quantified using above mentioned steps and graph 
plotted (Fig. 7D) 
 
Fig. 7. 
GluA1 levels decrease with UBQL2 overexpression. (A)Culture hippocampal 
neurons at DIV11 were transfected with GFP and with and without UBQL2. They 
were immunostained with anti- GluA1 antibodies. The number of puncta on a piece 
of dendrite was calculated. The boxed area is enlarged below. (B) This shows the 
quantified density of puncta per 10µm of dendrite and intensity of GluA1 puncta. 
The density of GluA1 in GFP control was 0.57 ± 0.05, n = 13 and density of GluA1 
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in GFP+UBQL2 was 0.33 ± 0.02, n = 13; p < 0.05. The intensity of puncta in GFP 
control was 30127 ± 5792, n = 14 and intensity in GFP+UBQL2 was 16587 ± 2969, 
n = 14; p < 0.05. (C) HEK293T cells were transfected with GluA1 and with and 
without UBQL2. The total levels of GluA1 was analyzed using western blotting and 
probing with anti-GluA1 antibodies. (D) GluA1 expression was significantly 
reduced with the over-expression of UBQLN (GluA1 = 0.100 ± 0.05; UBQLN: = 
0.72 ± 0.06, n = 4; p < 0.01) (Courtesy to Ouyang Guo) 
 
3.5 Overexpression of UBQL2 leads to reduced spine density 
Further, to study if the UBQL2 overexpression caused any difference in spine 
number, cultured hippocampal neurons were transfected with membrane GFP with 
and without UBQL2. 3 days after transfection, the cells were fixed and mounted to 
look at the spine changes. The neurons having UBQL2 showed lesser spine 
density compared to the control (Fig. 8A). The spine number per 10µm was 
counted and plotted. The results are summarized in Fig. 8B. This indicates a role 





Spine density decrease with UBQL2 overexpression (A) Cultured DIV 11 
hippocampal neurons were transfected with mGFP with or without UBQL2. The 
cells were visualized for spine changes and the number of spines per 10µm was 
counted manually using ImageJ. (B) The changes in spine was plotted. The 
number of spines per 10µm in mGFP control was 6.10 ± 0.03, n = 14 and in mGFP 
with UBQL2 was 3.93 ± 0.38, n = 2; p < 0.05 
3.6 Co-localization of UBQL2 and rpn3 subunit of Proteasome  
To investigate if UBQL2 can interact with the proteasome, DIV 14 hippocampal 
neurons were fixed and double stained for UBQL2 and the lid subunit of the 
proteasome- Rpn3 using anti-UBQL2 antibody and anti-rpn3 antibody 
respectively. The puncta of a section of the dendrite was analyzed for co 
localization. It was seen that the UBQL2 co-localized with the proteasome subunit 
rpn3 along the dendrites. This indicates that there is an interaction of UBQL2 with 




3.7 Co-localization of GluA1 and rpn3 subunit of Proteasome 
From previous experiments we know that UBQL2 reduces GluA1 density (Fig. 7A, 
C) and UBQL2 co-localizes with proteasome (Fig. 9C). Thus, to determine if 
UBQL2 is responsible for bringing the GluA1 to the proteasome for degradation, 
the co-localization of GluA1 with the proteasome in the presence and absence of 
UBQL2 was assessed. 
The rat hippocampal neurons were transfected with GFP with and without UBQL2 
in DIV 11 cultured neurons. One set of UBQL2 transfection, the cells were treated 
with a proteasomal inhibitor MG132 to accumulate GluA1 and look for co-
localization between GluA1 and proteasome in the neurons. Thus, blocking 
proteasome allows UBQL2 to deliver GluA1 to the proteasome but doesn’t allow 
proteasome degradation.  
The GluA1 and rpn3 subunit were stained with anti-GluA1 antibodies and anti-rpn3 
antibodies respectively. The total area co-localized was calculated using ImageJ 
and the graph plotted (Fig. 9A and 9B). The results show that there is greater co-
localization of GluA1(red) with rpn3(Blue) when UBQL2 is transfected compared 
to the control cells that has no UBQL2 transfected. The merge of red and blue 
channels forming magenta colored puncta can be seen in UBQL2 transfected cells 
(Fig.  9A). Further, the levels of GluA1 and rpn3 co-localization in the cells 
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increased due to GluA1 accumulation by proteasome blocker-MG132. This shows 




Co-localization of UBQL2 and GluA1 with rpn-3.  (A)Cultured DIV11 hippocampal 
neurons were double stained with anti-GluA1 and anti-rpn antibodies. The merge 
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of red and blue channels indicates the co-localization of GluA1 with proteasome 
subunit rpn-3. The boxed area is enlarged and the arrows shows co-localized 
puncta between GluA1 and rpn-3. (B) The graph plotted is the calculated percent 
area co-localized between the GluA1 and rpn3 channels. Each piece of dendrite 
was analyzed for area co-localized in µm2 (GFP = 1.65 ± 0.45, GFP+UBQL2 = 3.24 
± 0.82, GFP+UBQL2+MG132 = 3.82 ± 0.31 (C)Double staining with anti-UBQL2 
and anti-rpn3 indicates the co-localization of UBQL2 with rpn3 subunit of AMPARs. 
The boxed area is enlarged and the puncta distribution between UBQL2 and rpn3 
indicates co-localization. This is indicated by arrows on the enlarged figures. The 
merged figure shows the yellow punctate arising from the co-localization from 
Rhoda mine(red) and GFP signals(green). 
 
3.8 UBQL2 P497H binds to polyubiquitinated protein but is deficient in binding to 
proteasome. 
To study the role of UBQL2 in GluA1 proteasomal degradation, a UBQL2 mutant 
plasmid was used. This mutant UBQL2 has a single amino acid mutation in its PXX 
domain where Proline(P) 497 is mutated to Histidine (H). This mutant UBQL2 
blocks proteasomal degradation and therefore leads to protein accumulation in the 
cell (Chang Lydia and Mervyn J Monteiro, 2015). 
To study if UBQL2 P497H is able to block GluA1 degradation, HEK293T cells were 
transfected with GFP tagged GluA1 along with either WT UBQL2 or UBQL2 P497H 
respectively. The transfected cells under microscope were assessed for the GFP 
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tagged GluA1 cells. It was seen that GFP tagged GluA1 levels increased when 
UBQL2 mutant was transfected compared to the control cells GFP-GluA1 and WT 
UBQL2 cells. The total GluA1 levels were probed by western blotting using anti-
GFP antibodies. As shown, the levels of GluA1 increased when a mutant UBQL2 
was transfected compared to the WT UBQL2 (Fig. 10A, D). The total levels of 
UBQL2, rpn were slightly increased in mutant UBQL2 condition (Fig. 10D).  
To determine whether this mutant form is capable of interacting with GluA1, 
UBQL2 was immunoprecipitated with anti-UBQL2 antibodies. GluA1 interaction 
was evaluated by probing with anti-GluA1 antibodies. It was seen that both WT 
UBQL2 and the mutant UBQL2 were capable of interacting with GluA1. Thus, this 
shows that the mutation in UBQL2 does not affect the binding with the 
polyubiquitinated GluA1(Fig. 10B).  
 
To investigate the binding capacities of the mutant with proteasome subunit rpn-3, 
the rpn3 was immunoprecipitated using the anti-rpn3 antibodies. The binding of 
UBQL2 was seen by probing for anti-UBQL2 antibodies. It was seen that the 
mutant UBQL2 was incapable of binding to the proteasome and the WT UBQL2 
can efficiently bind to the proteasome (Fig. 10C). Thus, the mutant UBQL2 is 








Mutant UBQL2 leads to accumulation of GluA1 in HEK cells. (A) HEK cells 
transfected with GFP tagged GluA1 along with UBQL2 or mutant UBQL2. GFP 
florescence indicating GluA1 levels are high with mutant UBQL2 transfection 
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compared to the control and WT UBQL2 condition. Exposure time for all were 
around 450ms. (B) The transfected cells were lysed with RIPA lysis buffer and the 
proteins were quantified using a western blotting. The cell lysates were 
immunoprecipitated with anti-UBQL2 antibodies and probed with anti-GluA1 
antibodies. The confirmation was done by re-probing with anti-UBQL2 antibodies. 
(C) The proteasome subunit rpn-3 was immunoprecipitated using anti-rpn3 
antibodies and UBQL2 was probed using anti-UBQL2 antibodies. The confirmation 
of the pull down was done by re-probing with anti-rpn3 antibodies. (D) The western 
bands show increase in the levels of GluA1 when mutant UBQL2 is transfected 













AMPARs are important for excitatory synaptic transmission in the CNS. Dynamic 
trafficking of AMPA receptors to and from the membrane is one of the major 
mechanism of synaptic plasticity including Hebbian and homeostatic plasticity (Lin 
et al. 2011). The regulation of the AMPARs are carried out by post translational 
modifications which occur in the C terminal end of the AMPARs subunits (Widagdo 
et al. 2017).  
Here, we have explored into one such regulatory mechanism of GluA1 subunit of 
AMPAR subunit which is ubiquitination. Several lines of evidence show that 
ubiquitination of GluA1 causes endocytosis of the receptor (Patrick et al. 2003). A 
number of E3 ubiquitin ligases are known to play an important role in this 
ubiquitination pathway. For example, one study showed that GluA1 ubiquitination 
is enhanced when Nedd4-1 is overexpressed in neurons (Lin et al. 2011) whereas 
others showed that shRNA-mediated knockdown of Nedd4-1 decreases the rate 
of GluA1 internalization (Schwarz et al. 2010).  
4.1 Fate of internalized receptors 
The fate of receptor endocytosis has been a much debated topic in past years. 
Several views were put forth over past decades. One study suggested how the 
fate of the internalized ubiquitinated protein depends on the ubiquitin chain length 
(Clague and Urbé et al. 2010). Mono and short ubiquitin tails are often internalized 
and degraded by the lysosome. Proteins tagged with more than 4 ubiquitin 
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molecules are targeted for proteasomal degradation. Others showed that 
administration of a proteasome blocker-MG132 led to decrease in the number of 
internalized GluA1 subunit in presence of AMPA (Patrick et.al, 2010). This study 
concluded that this inhibiting internalization might indicate a role of proteasomal 
degradation in AMPAR trafficking. Here, we focused on ubiquitin-proteasomal 
system of AMPARs and we study how such ubiquitin-tagged GluA1 subunit are 
delivered to the proteasome for degradation. Presumably, the Eps15 that mediates 
the internalization of AMPARs subunit leaves after endocytosis and the UBQL2 
binds to the ubi-tagged protein to deliver it to the proteasome. 
4.2 UBQL2 acts as a shuttling protein in bringing ubiquitin-tagged proteins to 
proteasome 
UBQL2 has been known to act as shuttling proteins that bind polyubiquitinated 
protein and deliver them to the proteasome for degradation (Han Seok Ko et al, 
2004). We asked whether UBQL2 is also a shuttling protein for bringing the GluA1 
subunit of AMPAR to the proteasome for degradation. To test our hypothesis, we 
first determined whether UBQL2 interacted with GluA1. The results of our co-
immunoprecipitation assays revealed strong interaction between UBQL2 and 
GluA1 in both HEK and rat brain lysates (Fig. 4B, C). There was also strong co-
localization between UBQL2 and GluA1 in neurons (Fig. 4A). Our study further 
demonstrated that UBQL2 binding to GluA1 is ubi dependent. A polyubiquitin tail 
is formed at the lysine 868 residues in the C-terminal portion of GluA1.  
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GluA1 with a C terminal deletion displayed lesser UBQL2 binding compared to full-
length GluA1(Fig. 5A). Also, GluA1 with all 4 lysines mutated to arginine results in 
reduced binding of UBQL2(Fig. 6A). Thus, these results shows that UBQL2 binding 
to GluA1 is ubiquitin dependent and that a C-terminal deletion diminishes the 
interaction with UBQL2.  
We next showed that UBQL2 co-localizes with rpn3 subunit of proteasome (Fig. 
9C). This provides evidence that UBQL2 might be playing an important regulatory 
function in GluA1 degradation pathways.  
4.3 AMPARs abundance and UBQL2 binding to proteasome 
To test for functional role of UBQL2, we overexpressed UBQL2 in rat hippocampal 
neurons. UBQL2 overexpression was found to decrease the GluA1 density and 
intensity in neurons (Fig. 7A). The same experiment performed in HEK293T cells 
also showed reduced levels of GluA1 in the presence of UBQL2(Fig. 7C).  Since 
UBQL2 has long been known to act as shuttling protein in the proteasomal 
degradation pathway, this decrease in GluA1 provides evidence that UBQL2 
brings the GluA1 to proteasome for degradation. Further, the co-localization 
assays between GluA1 and rpn3 shows increased co-localization in presence of 
UBQL2 than in control cells (Fig. 9A). 
Previous studies show that the mutant UBQL2 having one amino acid change from 
P 497 to H slows down degradation of c-myc, a very common protein that is 
proteasomally degraded (Chang et al. 2015). Expression of the UBQL2 mutant 
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caused an increase in the levels of protein substrate (Chang et al. 2015). We 
transfected the mutant UBQL2 in HEK293T cells. We saw that the mutant UBQL2 
led to an increase in the levels of GluA1 protein in HEK293T cells.  
4.4 Spine density decreases with overexpression of UBQL2 
Overexpression of UBQL2 also causes lesser mature spines (Fig. 8A, B). The 
spine density decrease may be due to lesser synaptic connections formed 
between the post and pre-synaptic neurons. In many neurodegenerative disorders, 
alterations in synapses and dendritic spines are some of the earliest 
manifestations of the disease. Since UBQL2 is also involved in the degradation 
pathway of several other proteins, there might be a decrease in synaptic proteins 
leading to decreased synapse formation. This is seen as fewer number of spines 
formed. Further experiments are required to see if overexpression of UBQL2 
causes decrease in dendritic arborization. 
4.5 UBQL2 P497H mutation and interaction of UBQL2 and GluA1 
Fig. 10D shows that the levels of GluA1 increased in the presence of mutated 
UBQL2. The immunoprecipitation assays showed that both WT-UBQL2 and 
Mutant UBQL2 can interact with the polyubiquitinated GluA1. But the mutant 
UBQL2 had decreased affinity to the proteasome. This explains why the increase 
in GluA1 is seen in the mutant condition. Supporting our hypothesis, we show that 
the mutant UBQL2 is unable to interact with proteasome which explains the 
increased levels of GluA1 with mutant UBQL2 transfection. 
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4.6 Summary and Future directions 
As shown in Fig. 11, our model depicts that once GluA1 is internalized upon 
ubiquitination, UBQL2 binds to the lysine 868 residue in the C-terminal region of 
GluA1. Binding of UBQL2 then facilitates degradation of the GluA1 by the 
proteasome. This occurs because UBQL2 interacts with the proteasome and 
brings GluA1 closer to proteasome for degradation.  
Our results indicate a possible role for UBQL2 in the degradation pathway of 
GluA1. Our future directions will focus on knocking down UBQL2 and determining 
the effects of this on GluA1 levels in neurons and HEK293T cells. We predict that 
knocking down UBQL2 will increase the levels of GluA1 since there is no UBQL2 
to deliver the GluA1 to the proteasome for degradation.  
Other works related to this will focus on studying the involvement of UBQL2 in the 
AD conditions. Previously published data from our lab shows that GluA1 is reduced 
in the presence of Aβ treatment for 24hrs and 48hrs (Zhang, Yamin et al. 2018).  
We want to investigate if the knockdown of UBQL2 is able to block the Aβ effect 
and lead to increase in levels of GluA1 in brain. This will provide a translational 






Schematic diagram depicting the hypothesis. The GluA1 subunit of the AMPAR is 
present on the post synaptic end of the neurons. Binding of a ligand such as 
glutamate or AMPA leads to opening of the channel.1) The GluA1 gets 
ubiquitinated by the ubiquitination associated enzymes E1, E2 and E3 ubiquitin 
ligases. They add multiple ubiquitin molecules onto the GluA1 protein at the site of 
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lysine 868. Red dots indicate lysine sites on C terminal tail of GluA1 2) The GluA1 
is internalized in an activity dependent manner via the eps15 mediated endocytic 
pathway. 3) For proteasomal degradation, the eps15 is removed and UBQL2 binds 
to ubi-tagged GluA1 through the UBA domain. UBQL2 binds to the ubiquitin chain 
on lysine 868 residues in the C terminal end of GluA1. UBQL2 also binds to the 
rpn3 lid subunit of the proteasome through the UBL domain. 4) It then brings the 
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